EA201071040A1 - Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40 - Google Patents

Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40

Info

Publication number
EA201071040A1
EA201071040A1 EA201071040A EA201071040A EA201071040A1 EA 201071040 A1 EA201071040 A1 EA 201071040A1 EA 201071040 A EA201071040 A EA 201071040A EA 201071040 A EA201071040 A EA 201071040A EA 201071040 A1 EA201071040 A1 EA 201071040A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cx3cr1
benzyl
mcp
expression
diseases caused
Prior art date
Application number
EA201071040A
Other languages
English (en)
Other versions
EA019711B1 (ru
Inventor
Анджело Гульельмотти
Гвидо Фурлотти
Джорджина Мангано
Никола Каццолла
Барбара Гарофало
Original Assignee
Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. filed Critical Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А.
Publication of EA201071040A1 publication Critical patent/EA201071040A1/ru
Publication of EA019711B1 publication Critical patent/EA019711B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Настоящее изобретение относится к новым производным 1-бензил-3-гидроксиметилиндазола в соответствии с приведенной в формуле изобретения формулой (I) и к фармацевтическим композициям, содержащим их вместе с фармацевтически приемлемым носителем. Кроме того, настоящее изобретение относится к применению производных 1-бензил-3-гидроксиметилиндазола для приготовления фармацевтической композиции, которая активна при лечении заболеваний, обусловленных экспрессией МСР-1, CX3CR1 и р40, и к их применению в способе лечения или предупреждения заболеваний, обусловленных экспрессией МСР-1, CX3CR1 и р40.
EA201071040A 2008-03-07 2009-03-05 ПРОИЗВОДНЫЕ 1-БЕНЗИЛ-3-ГИДРОКСИМЕТИЛИНДАЗОЛА, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, ОБУСЛОВЛЕННЫХ ЭКСПРЕССИЕЙ МСР-1, СХ3CR1 ИЛИ р40 EA019711B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08425139 2008-03-07
PCT/EP2009/052590 WO2009109618A2 (en) 2008-03-07 2009-03-05 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40

Publications (2)

Publication Number Publication Date
EA201071040A1 true EA201071040A1 (ru) 2011-02-28
EA019711B1 EA019711B1 (ru) 2014-05-30

Family

ID=39671487

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201071038A EA018241B1 (ru) 2008-03-07 2009-03-05 ПРОИЗВОДНЫЕ 1-БЕНЗИЛ-3-ГИДРОКСИМЕТИЛИНДАЗОЛА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ОСНОВАННЫХ НА ЭКСПРЕССИИ MCP-1, CX3CR1 И p40
EA201071040A EA019711B1 (ru) 2008-03-07 2009-03-05 ПРОИЗВОДНЫЕ 1-БЕНЗИЛ-3-ГИДРОКСИМЕТИЛИНДАЗОЛА, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, ОБУСЛОВЛЕННЫХ ЭКСПРЕССИЕЙ МСР-1, СХ3CR1 ИЛИ р40

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201071038A EA018241B1 (ru) 2008-03-07 2009-03-05 ПРОИЗВОДНЫЕ 1-БЕНЗИЛ-3-ГИДРОКСИМЕТИЛИНДАЗОЛА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ОСНОВАННЫХ НА ЭКСПРЕССИИ MCP-1, CX3CR1 И p40

Country Status (25)

Country Link
US (3) US7919518B2 (ru)
EP (3) EP2254869B1 (ru)
JP (2) JP5509099B2 (ru)
KR (2) KR101581828B1 (ru)
CN (2) CN101945855B (ru)
AR (2) AR070811A1 (ru)
AU (2) AU2009221083B2 (ru)
BR (2) BRPI0907977A2 (ru)
CA (2) CA2712703C (ru)
CY (2) CY1117584T1 (ru)
DK (2) DK2254870T3 (ru)
EA (2) EA018241B1 (ru)
ES (2) ES2569330T3 (ru)
GE (2) GEP20135912B (ru)
HR (2) HRP20160462T1 (ru)
HU (1) HUE027098T2 (ru)
IL (3) IL206893A0 (ru)
LT (1) LT2254869T (ru)
MX (2) MX2010009623A (ru)
PL (2) PL2254869T3 (ru)
PT (1) PT2254869T (ru)
SG (1) SG188177A1 (ru)
SI (2) SI2254870T1 (ru)
UA (2) UA103605C2 (ru)
WO (2) WO2009109618A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2771875C2 (ru) * 2016-12-12 2022-05-13 Ветторе, Ллс Гетероциклические ингибиторы МСТ4

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919518B2 (en) * 2008-03-07 2011-04-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
GEP20135913B (en) 2008-03-07 2013-08-26 Acraf 1-benzyl-3-hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1 and cx3cr1 expression
HUE047318T2 (hu) * 2008-03-07 2020-04-28 Acraf 1-benzil-3-hidroximetilindazol származékok és alkalmazásuk az MCP-1, CX3CR1 és P40 expresszióján alapuló betegségek kezelésében
JP5640086B2 (ja) 2009-08-03 2014-12-10 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニＡｚｉｅｎｄｅ Ｃｈｉｍｉｃｈｅ Ｒｉｕｎｉｔｅ Ａｎｇｅｌｉｎｉ Ｆｒａｎｃｅｓｃｏ Ａ．Ｃ．Ｒ．Ａ．Ｆ．Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ １−ベンジル−３−ヒドロキシメチル−１ｈ−インダゾール及びその誘導体の製造方法並びに必要なマグネシウム中間体
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US8999292B2 (en) * 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
CA2911041C (en) * 2012-05-01 2020-12-15 Shelley Romayne BOYD Methods for treating and diagnosing blinding eye diseases
JP2015521183A (ja) 2012-05-18 2015-07-27 サノフイ ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用
ES2612205T3 (es) 2012-05-18 2017-05-12 Sanofi Derivados de pirazol y su uso como antagonistas de LPAR5
MX2015005846A (es) 2012-11-09 2015-12-16 Colgate Palmolive Co Copolimeros de bloque para proteccion del esmalte dental.
DK3142664T3 (da) * 2014-05-15 2020-03-09 Translatum Medicus Inc Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
KR102653599B1 (ko) * 2015-06-12 2024-04-01 베토어 엘엘씨 질환 치료용 mct4 저해제
US20180221339A1 (en) * 2015-06-16 2018-08-09 Translatum Medicus, Inc. Compositions and methods for treating and diagnosing ocular disorders
US10214492B2 (en) * 2016-12-12 2019-02-26 Vettore, LLC Heterocyclic inhibitors of MCT4
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
US11753382B2 (en) 2019-06-25 2023-09-12 Translatum Medicus Inc. Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
CN113929627A (zh) * 2021-10-19 2022-01-14 吕梁学院 一种宾达利的合成方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US364371A (en) * 1887-06-07 peice
US416359A (en) * 1889-12-03 Sash-fastener
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
EP1185528A4 (en) 1999-06-17 2003-03-26 Shionogi Biores Corp INHIBITORS OF IL-12 PRODUCTION
EP1188438A1 (en) 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en) 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
JP4234439B2 (ja) 2001-03-15 2009-03-04 生化学工業株式会社 Ｉｌ−１２発現調節剤
RU2320658C2 (ru) 2001-11-30 2008-03-27 Синта Фармасьютикалз Корпорейшн Производные пиримидина
EP1675862A1 (en) 2003-10-07 2006-07-05 AstraZeneca AB New 2-substituted, 4-amino-thiazolo 4,5-d pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
EP1806145B1 (en) * 2004-10-29 2017-08-16 Eisai R&D Management Co., Ltd. Remedy for inflammatory diseases
CA2586870A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
EP1827447A1 (en) 2004-11-19 2007-09-05 Synta Pharmaceuticals Corporation Pyrimidine compounds and uses thereof
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
GEP20135913B (en) 2008-03-07 2013-08-26 Acraf 1-benzyl-3-hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1 and cx3cr1 expression
US7919518B2 (en) 2008-03-07 2011-04-05 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and p40
HUE047318T2 (hu) 2008-03-07 2020-04-28 Acraf 1-benzil-3-hidroximetilindazol származékok és alkalmazásuk az MCP-1, CX3CR1 és P40 expresszióján alapuló betegségek kezelésében

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2771875C2 (ru) * 2016-12-12 2022-05-13 Ветторе, Ллс Гетероциклические ингибиторы МСТ4

Also Published As

Publication number Publication date
CY1117584T1 (el) 2017-04-26
AU2009221089B2 (en) 2013-12-05
JP5509101B2 (ja) 2014-06-04
CA2712403C (en) 2017-06-06
IL206893A0 (en) 2010-12-30
ES2569330T3 (es) 2016-05-10
CA2712703C (en) 2016-10-11
JP2011513365A (ja) 2011-04-28
EP2254870B1 (en) 2016-02-24
US8835481B2 (en) 2014-09-16
EA019711B1 (ru) 2014-05-30
DK2254869T3 (en) 2017-09-04
UA105170C2 (en) 2014-04-25
AU2009221083B2 (en) 2013-11-28
US7919518B2 (en) 2011-04-05
JP2011513367A (ja) 2011-04-28
SI2254870T1 (sl) 2016-05-31
EP2254869B1 (en) 2017-05-31
ES2637009T3 (es) 2017-10-10
US20100311744A1 (en) 2010-12-09
KR101581828B1 (ko) 2015-12-31
MX2010009626A (es) 2010-12-20
IL215579A (en) 2015-06-30
PT2254869T (pt) 2017-07-18
CA2712403A1 (en) 2009-09-11
GEP20135912B (en) 2013-08-26
EA201071038A1 (ru) 2011-02-28
HRP20171208T1 (hr) 2017-10-06
SI2254869T1 (sl) 2017-10-30
CN101945855B (zh) 2014-12-17
GEP20135983B (en) 2013-12-10
IL207131A (en) 2013-02-28
HRP20160462T1 (hr) 2016-06-03
KR20100133957A (ko) 2010-12-22
US8283348B2 (en) 2012-10-09
CN101952256B (zh) 2016-03-16
PL2254870T3 (pl) 2016-07-29
JP5509099B2 (ja) 2014-06-04
IL215579A0 (en) 2011-11-30
UA103605C2 (en) 2013-11-11
KR101599867B1 (ko) 2016-03-04
US20110003874A1 (en) 2011-01-06
WO2009109613A2 (en) 2009-09-11
KR20100131432A (ko) 2010-12-15
AU2009221083A1 (en) 2009-09-11
AR070811A1 (es) 2010-05-05
IL207131A0 (en) 2010-12-30
AR070810A1 (es) 2010-05-05
US20110160205A1 (en) 2011-06-30
CY1119252T1 (el) 2018-02-14
DK2254870T3 (en) 2016-05-17
EP3181551A1 (en) 2017-06-21
WO2009109613A3 (en) 2009-12-10
WO2009109618A3 (en) 2009-12-10
WO2009109618A2 (en) 2009-09-11
AU2009221089A1 (en) 2009-09-11
BRPI0907976A2 (pt) 2015-08-04
BRPI0907977A2 (pt) 2015-08-04
SG188177A1 (en) 2013-03-28
EA018241B1 (ru) 2013-06-28
HUE027098T2 (en) 2016-08-29
CA2712703A1 (en) 2009-09-11
CN101952256A (zh) 2011-01-19
PL2254869T3 (pl) 2017-10-31
LT2254869T (lt) 2017-08-10
EP2254869A2 (en) 2010-12-01
CN101945855A (zh) 2011-01-12
MX2010009623A (es) 2010-09-28
EP2254870A2 (en) 2010-12-01

Similar Documents

Publication Publication Date Title
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA026385B9 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
MD20130095A2 (ru) Конденсированные соединения бензоксазепинонов в качестве модуляторов ионных каналов
EA201391532A1 (ru) Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
EA201100503A1 (ru) Глюкозидные производные и их применения
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201390198A1 (ru) Гетероциклическое соединение
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU